| Xi Lin, | |
|
4373 Union St Ste 1b, Flushing, NY 11355-3191 | |
| (718) 886-3877 | |
| Not Available |
| Full Name | Xi Lin |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 4373 Union St Ste 1b, Flushing, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043078785 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 352895 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Xi Lin, 57 Elmtree Ln, Jericho, NY 11753-2644 Ph: () - | Xi Lin, 4373 Union St Ste 1b, Flushing, NY 11355-3191 Ph: (718) 886-3877 |
News Archive
Scientists have known for more than 40 years that the synthetic pesticide DDT is harmful to bird habitats and a threat to the environment.
Bristol-Myers Squibb Company and Mead Johnson Nutrition Company announced today that based on preliminary results the offer by Bristol-Myers Squibb to exchange up to 170,000,000 shares of common stock of Mead Johnson for outstanding shares of Bristol-Myers Squibb common stock that are validly tendered and not validly withdrawn was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, on December 17, 2009.
Tests have shown that the strain in Haiti's cholera outbreak is similar to cholera strains found in South Asia, the CDC said on Monday, Agence France-Presse reports (11/1).
Today's hospitals are challenged to become better prepared to manage large numbers of patients from mass casualty incidents (MCI), hazardous material incidents (HAZMAT), or in extreme cases, attacks using weapons of mass destruction (WMD).
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 8 days ago
Dr. Haifan Chen, M.D., D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3808 Union St Ste 3l, Flushing, NY 11354 Phone: 718-939-5213 Fax: 718-939-8949 | |
Ms. Zu Yu Chen, D.O Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13739 45th Ave, Flushing, NY 11355 Phone: 929-362-3006 | |
Dr. Paul Xiaopu Li, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13336 41st Rd Ste 1, Flushing, NY 11355 Phone: 718-568-9538 Fax: 718-961-1393 | |
Jim Li, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 14355 37th Ave Fl 1, Flushing, NY 11354 Phone: 718-268-0878 | |
Dalai Zhou, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 136-20 38th Ave, Suite 6c, Flushing, NY 11354 Phone: 718-886-8299 Fax: 718-886-3669 | |
Jessica Truong, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3808 Union St Ste 3i, Flushing, NY 11354 Phone: 917-621-8999 |